Sign in Subscribe
Tariffs

Uncertainty Looms Over Biotech Industry as Analysts Warn of Potential Tariffs, Interest Rate Drop, and Tax Changes

Strategic Insights

— 1 min read

Biotech analysts at EY are expressing concerns about the industry's prospects due to various economic uncertainties, including potential pharmaceutical tariffs, tax rates, and interest rates. The analysts are finding it challenging to assess trends and make projections in their 35th annual "Biotech Beyond Borders" report. Geopolitical factors, particularly in China, are also affecting the industry, with the country emerging as a source of innovation. Despite these challenges, EY advises biotech companies to focus on fundamentals and allocate resources carefully, as there will be opportunities for those who take calculated risks.

Key Takeaways:

  • The biotech industry is facing significant uncertainty due to potential pharmaceutical tariffs, tax rates, and interest rates, making it challenging for analysts to assess trends and make projections.
  • EY's 35th annual "Biotech Beyond Borders" report highlights the need for biotech companies to be cautious and focus on fundamentals in order to navigate the current economic environment.
  • Geopolitical factors, particularly in China, are also affecting the industry, with the country emerging as a source of innovation and biopharma investment.
  • The industry is witnessing a trend of biased towards mergers and acquisitions (M&A), with pharmaceutical companies opting for deals that offer clinical or regulatory milestones.
  • The top 20 pharma companies have a combined cash stockpile of $1.27 trillion, which can be used to accelerate M&A activity once uncertainty subsides.
  • The industry's growth gap is expected to reach $300 billion in revenue through 2028 due to oncoming patent expirations for several of the world's best-selling drugs.

Statistics:

  • Biotech financing decreased by 10% in 2024 to $73 billion.
  • Early-stage funding was up 10% in 2024, but there were 20% fewer early-stage deals.
  • The average transaction size in the biopharma industry was $1.4 billion in 2024, down from $2.5 billion in 2023.
  • The top 20 pharma companies have a combined cash stockpile of $1.27 trillion.

Sources:

  • EY's 35th annual "Biotech Beyond Borders" report
  • EY Americas Life Sciences Sector Leader Arda Ural, Ph.D.
  • EY's Principal, Life Sciences Strategy Ashwin Singhania
  • EY Americas Life Sciences Sector and Biotechnology Leader Rich Ramko

Read more